MiniMed Group, Inc. Common Stock
NASDAQ:MMEDMedical - Care Facilities
+$0.40 today
- Market cap
- $4.78B
- Beta
- -3.63
- P/E (TTM)
- -14.2
- EPS (TTM)
- -$1.91
Volume 4.70M
Average 0.95M
MMED Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
MiniMed Group, Inc. Common StockNASDAQ: MMED
Capital Expenditures · Q1 FY2026 · quarter ended Jul 2026
Capital expenditures of -$41M in Q1 FY2026
Q1 FY2026 capital expenditures was -$41M. Trailing-twelve-month capital expenditures was -$211M. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Capital expenditures amounted to 7.2% of revenue in FY2025, unchanged from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near -$41M or moves back toward the trailing-twelve-month quarterly average of -$52.75M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (223M) USD
- Year-over-year change
- -15.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2026-04-24 | (223M) | -15.5% |
| FY2024 | 2025-04-30 | (193M) | -30.4% |
| FY2023 | 2024-04-30 | (148M) | +11.4% |
| FY2022 | 2023-04-30 | (167M) | — |
Capital Expenditures vs competitors
How MMED compares with its peers on the latest reported figures
- MMED's LTM Jul 2026 capital expenditures of $211M is the 4th largest of the 7 companies compared; the peer median is $118.08M.
- Capital expenditures amounts to 6.5% of revenue for MMED, versus a peer median of 5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.9B | +3.3% | +9.3% | 5.1% | |
| LTM Jun 2026 | $343.7M | -17.6% | -0.1% | 6.9% | |
| LTM Jun 2026 | $212.9M | +80.1% | +6.8% | 7.0% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $211M | — | +10.1% | 6.5% |
| LTM Mar 2026 | $23.25M | +31.1% | -16.4% | 2.3% | |
| LTM Mar 2026 | $6.34M | +90.9% | +90.0% | 5.8% | |
| LTM Mar 2026 | $793K | -66.4% | +52.9% | 1.9% | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding MMED) | $118.08M | +17.2% | +8.0% | 5.4% | |
Competitors are the stored peer set for MMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2023 | FY2023 Apr 2024 | FY2024 Apr 2025 | FY2025 Apr 2026 |
|---|---|---|---|---|
| Net Income | (92M) | (107M) | (198M) | (317M) |
| Depreciation & Amortization | 115M | 129M | 143M | 156M |
| Deferred Income Tax | (11M) | 3M | (2M) | (54M) |
| Stock-Based Compensation | 35M | 38M | 41M | 46M |
| Change in Working Capital | (90M) | (74M) | 122M | (166M) |
| Accounts Receivables | (70M) | (105M) | (66M) | (538M) |
| Inventory | (28M) | 5M | (19M) | (29M) |
| Accounts Payables | 14M | (4M) | 191M | 41M |
| Other Working Capital | (6M) | 30M | 16M | 360M |
| Other Non-Cash Items | 37M | 52M | 34M | 138M |
| Operating Cash Flow | (6M) | 41M | 140M | (197M) |
| Capital Expenditures | (167M) | (148M) | (193M) | (223M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (13M) | (5M) | 0 | 0 |
| Sales of Investments | 0 | 11M | 0 | 0 |
| Other Investing Activities | 0 | (15M) | 0 | (10M) |
| Investing Cash Flow | (180M) | (157M) | (193M) | (233M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 538M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 185M | 112M | 10M | 178M |
| Financing Cash Flow | 185M | 112M | 10M | 716M |
| Effect of Forex Changes | 0 | 0 | 0 | 1M |
| Net Change in Cash | (2M) | (4M) | (43M) | 287M |
| Free Cash Flow | (173M) | (107M) | (53M) | (420M) |
MiniMed Group, Inc. Common Stock
NASDAQ:MMED
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.